- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.04. | Transcode Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 07.04. | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.03. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.02. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 | 460 | PR Newswire | BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics... ► Artikel lesen | |
| 06.01. | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.12.25 | TransCode Therapeutics appoints Jack E. Stover to board of directors | 2 | Investing.com | ||
| 22.12.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.12.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial | 285 | PR Newswire | BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate... ► Artikel lesen | |
| 11.12.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.11.25 | TransCode Therapeutics appoints Michel Janicot as development officer | 1 | Investing.com | ||
| 14.10.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO | 302 | PR Newswire | Safety primary endpoint achieved
Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial
RECIST data with... ► Artikel lesen | |
| 08.10.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology ... | 287 | PR Newswire | TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences
Concurrent equity investment of $25 Million from CK Life Sciences... ► Artikel lesen | |
| 08.05.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 373 | PR Newswire | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
| 05.05.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split | 469 | PR Newswire | BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively... ► Artikel lesen | |
| 02.05.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-28 Reverse Stock Split | 299 | PR Newswire | Split designed to achieve compliance with Nasdaq minimum bid price requirements
BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ)... ► Artikel lesen | |
| 01.05.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer | 209 | PR Newswire | A total of 13 patients treated with four escalating doses of TTX-MC138
No significant safety or dose limiting toxicities reported
Two patients have so far maintained... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,15 | +0,22 % | Durchbruch in der Psychotherapie: Emyria meldet 50% Remission - Ein neuer "BioNTech-Moment" für die Mental-Health-Branche? | ||
| QIAGEN | 32,580 | +0,12 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| NOVAVAX | 6,960 | -0,85 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| PALATIN TECHNOLOGIES | 21,860 | +4,00 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BRAIN BIOTECH | 2,420 | -2,42 % | BRAIN BIOTECH AG - Stabilität als strategische Basis | ||
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,008 | +3,12 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,480 | -0,67 % | Cosciens Biopharma Inc: Cosciens Biopharma to exit U.S. reporting | ||
| XOMA ROYALTY | 32,400 | 0,00 % | XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements | Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-K, Annual Report | ||
| PHIO PHARMACEUTICALS | 1,200 | -2,44 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series | King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ORAGENICS | 0,685 | 0,00 % | Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal... ► Artikel lesen | |
| VIVUS | - | - | VIVUS B.V.: VIVUS Reinforces QSIVA's Clinical Efficacy and Safety in Obesity Management | - QSIVA offers clinically meaningful weight loss supported by a well-established safety profile, now available at a reduced price across Nordics and Poland
AMSTERDAM, March 25, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| TENAX THERAPEUTICS | 11,700 | +5,41 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer | Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) ("Tenax"... ► Artikel lesen | |
| BIOLINERX | 1,720 | +3,61 % | BioLineRx Ltd.: BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) | GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers
GLIX1 has demonstrated potent... ► Artikel lesen |
TRANSCODE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,080 (-0,91 %) liegt der Kurs bei 8,680 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.